Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
UTHR

UTHR - United Therapeutics Corp Stock Price, Fair Value and News

$467.31-9.47 (-1.99%)
Market Closed

76/100

UTHR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

76/100

UTHR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$616.66

Target 3M

$502.23

Target 6M

$537.87

UTHR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

UTHR Price Action

Last 7 days

-0.5%

Last 30 days

-7.1%

Last 90 days

3.0%

Trailing 12 Months

26.0%

UTHR RSI Chart

UTHR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

UTHR Valuation

Market Cap

20.1B

Price/Earnings (Trailing)

15.82

Price/Sales (Trailing)

6.43

EV/EBITDA

10.62

Price/Free Cashflow

17.93

UTHR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$616.66

Target 3M

$502.23

Target 6M

$537.87

UTHR Fundamentals

UTHR Revenue

Revenue (TTM)

3.1B

Rev. Growth (Yr)

6.76%

Rev. Growth (Qtr)

0.11%

UTHR Earnings

Earnings (TTM)

1.3B

Earnings Growth (Yr)

9.58%

Earnings Growth (Qtr)

9.43%

UTHR Profitability

EBT Margin

53.27%

Return on Equity

19.3%

Return on Assets

17.3%

Free Cashflow Yield

5.58%

UTHR Investor Care

Buy Backs (1Y)

3.56%

Diluted EPS (TTM)

26.42

UTHR Alerts

  • 4 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20253.0B3.1B3.1B0
20242.5B2.6B2.8B2.9B
20232.0B2.1B2.2B2.3B
20221.8B1.8B1.9B1.9B
20211.5B1.6B1.7B1.7B
20201.4B1.4B1.4B1.5B
20191.6B1.5B1.5B1.4B
20181.7B1.7B1.7B1.6B
20171.6B1.6B1.7B1.7B
20161.5B1.6B1.6B1.6B
20151.3B1.3B1.4B1.5B
20141.2B1.2B1.2B1.3B
2013957.0M1.0B1.1B1.1B
2012784.9M826.7M867.4M916.1M
2011629.5M678.5M711.7M743.2M
2010000592.9M
Get all data in R, Python etc through our Historical Stock Data APIs

About United Therapeutics Corp

UTHR
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
 CEO
 WEBSITEunither.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES985

United Therapeutics Corp Frequently Asked Questions

UTHR is the stock ticker symbol of United Therapeutics Corp. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of United Therapeutics Corp is 20.12 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check UTHR's fair value in chart for subscribers.

The fair value guage provides a quick view whether UTHR is over valued or under valued. Whether United Therapeutics Corp is cheap or expensive depends on the assumptions which impact United Therapeutics Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for UTHR.

As of Wed Jan 28 2026, UTHR's PE ratio (Price to Earnings) is 15.82 and Price to Sales (PS) ratio is 6.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. UTHR PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, United Therapeutics Corp has provided 0.143 (multiply by 100 for percentage) rate of return.